Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

lexon (uk) ltd - rifampicin - oral capsule - 300mg

Keňa - angličtina - Pharmacy and Poisons Board

macleods pharmaceuticals limited 304, atlanta arcade, marol church road, andheri - rifampicin bp 150 mg - capsule, hard - rifampicin bp 150 mg - antimycobacterials: antibiotics

Keňa - angličtina - Pharmacy and Poisons Board

macleods pharmaceuticals limited 304, atlanta arcade, marol church road, andheri - rifampicin bp 300 mg - capsule, hard - rifampicin bp 300 mg … - antimycobacterials: antibiotics

Andorra - katalánština - CedimCat (Centre d'Informació de Medicaments de Catalunya)

rifampicina - càpsules

Andorra - katalánština - CedimCat (Centre d'Informació de Medicaments de Catalunya)

rifampicina - càpsules

Nizozemsko - nizozemština - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

genzyme europe b.v. paasheuvelweg 25 1105 bp amsterdam - rifampicine 150 mg/stuk - capsule, hard - erythrosine (e 127) ; gelatine (e 441) ; indigokarmijn (e 132) ; magnesiumstearaat (e 470b) ; maÏszetmeel ; titaandioxide (e 171), - rifampicin

Nizozemsko - nizozemština - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

genzyme europe b.v. paasheuvelweg 25 1105 bp amsterdam - rifampicine 300 mg/stuk - capsule, hard - erythrosine (e 127) ; gelatine (e 441) ; indigokarmijn (e 132) ; magnesiumstearaat (e 470b) ; maÏszetmeel ; titaandioxide (e 171), - rifampicin

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - rifampicin, quantity: 300 mg - capsule, hard - excipient ingredients: purified talc; gelatin; purified water; ascorbic acid; magnesium stearate; brilliant blue fcf; colloidal anhydrous silica; sodium lauryl sulfate; titanium dioxide; erythrosine; lactose monohydrate - indications as at 5 december 2001 : tuberculosis. in the initial treatment and in retreatment of patients with tuberculosis, rifampicin must be used in conjunction with at least one other antituberculosis drug. leprosy - in the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the non-infectious state which may be expected to occur in three to four months of treatment. - as an alternative drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other anti-leprosy drugs. - as an alternative drug in all those patients having true drug allergy to the more commonly used anti-leprosy drugs.,meningococcal disease prophylaxis of meningococcal disease in close contacts of known cases and in carriers (rifampicin is not indicated for the treatment of meningococcal infections).,haemophilus influenzae prophylaxis of household contacts of patients with haemophilus influenzae type b.,buruli ulcer for the treatment of myc

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - rifampicin, quantity: 150 mg - capsule, hard - excipient ingredients: ascorbic acid; magnesium stearate; iron oxide red; colloidal anhydrous silica; purified water; lactose monohydrate; brilliant blue fcf; purified talc; iron oxide yellow; erythrosine; gelatin; sodium lauryl sulfate; titanium dioxide - indications as at 5 december 2001 : tuberculosis. in the initial treatment and in retreatment of patients with tuberculosis, rifampicin must be used in conjunction with at least one other antituberculosis drug. leprosy - in the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the non-infectious state which may be expected to occur in three to four months of treatment. - as an alternative drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other anti-leprosy drugs. - as an alternative drug in all those patients having true drug allergy to the more commonly used anti-leprosy drugs.,meningococcal disease prophylaxis of meningococcal disease in close contacts of known cases and in carriers (rifampicin is not indicated for the treatment of meningococcal infections).,haemophilus influenzae prophylaxis of household contacts of patients with haemophilus influenzae type b.,buruli ulcer for the treatment of myc

Brazílie - portugalština - ANVISA (Agência Nacional de Vigilância Sanitária)

fundaÇÃo para o remÉdio popular - furp - rifampicina - rifampicinas